Cargando…

The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis

Background. FOLFOXIRI plus Bevacizumab is one of the most frequently used first-line treatments for patients with BRAF-mutant colorectal cancer (CRC), while second-line treatment requires extensive further research. In this pooled analysis, we evaluate the impact of anti-angiogenics in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gelsomino, Fabio, Casadei-Gardini, Andrea, Rossini, Daniele, Boccaccino, Alessandra, Masi, Gianluca, Cremolini, Chiara, Spallanzani, Andrea, Viola, Massimo Giuseppe, Garajovà, Ingrid, Salati, Massimiliano, Elia, Maria Teresa, Caputo, Francesco, Santini, Chiara, Falcone, Alfredo, Cascinu, Stefano, Tamburini, Emiliano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226019/ https://www.ncbi.nlm.nih.gov/pubmed/32326305 http://dx.doi.org/10.3390/cancers12041022

Ejemplares similares

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
por: Caputo, Francesco, et al.
Publicado: (2019)

Early Onset Metastatic Colorectal Cancer: Current Insights and Clinical Management of a Rising Condition
por: Medici, Bianca, et al.
Publicado: (2023)

Synchronous and metachronous colorectal liver metastases: impact of primary tumor location on patterns of recurrence and survival after hepatic resection
por: Garajova, Ingrid, et al.
Publicado: (2021)

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
por: Demurtas, Laura, et al.
Publicado: (2017)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
por: Gelsomino, Fabio, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
por: Marmorino, Federica, et al.
Publicado: (2020)

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
por: Rossini, D., et al.
Publicado: (2021)

Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies
por: Fanotto, Valentina, et al.
Publicado: (2023)

New Horizons for Personalised Treatment in Gastroesophageal Cancer
por: Salati, Massimiliano, et al.
Publicado: (2022)

Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
por: Rossini, Daniele, et al.
Publicado: (2022)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study
por: Moretto, Roberto, et al.
Publicado: (2023)

Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials
por: Casadei Gardini, Andrea, et al.
Publicado: (2019)

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
por: Antoniotti, Carlotta, et al.
Publicado: (2020)

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
por: Borelli, Beatrice, et al.
Publicado: (2018)

Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
por: Boccaccino, A., et al.
Publicado: (2022)

BRAF-mutated metastatic colorectal cancer between past and future
por: Cremolini, Chiara, et al.
Publicado: (2015)

Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis
por: Garajová, Ingrid, et al.
Publicado: (2023)

Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN)
por: Fornaro, Lorenzo, et al.
Publicado: (2021)

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
por: Cremolini, Chiara, et al.
Publicado: (2017)

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy
por: Salati, Massimiliano, et al.
Publicado: (2022)

Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable
por: Ongaro, Elena, et al.
Publicado: (2019)

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2016)

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial
por: Marmorino, Federica, et al.
Publicado: (2019)

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
por: Rossini, Daniele, et al.
Publicado: (2020)

Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy
por: Randon, Giovanni, et al.
Publicado: (2022)

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
por: Casadei Gardini, Andrea, et al.
Publicado: (2017)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Optimizing the Continuum of Care in Gastric Cancer
por: Riccò, Beatrice, et al.
Publicado: (2023)

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
por: Cremolini, Chiara, et al.
Publicado: (2017)

Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
por: Garajová, Ingrid, et al.
Publicado: (2023)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
por: Martini, G., et al.
Publicado: (2023)

The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer
por: Antoniotti, Carlotta, et al.
Publicado: (2018)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study
por: Borelli, B., et al.
Publicado: (2021)

Exploring the Outcome of Disappearance or Small Remnants of Colorectal Liver Metastases during First-Line Chemotherapy on Hepatobiliary Contrast-Enhanced and Diffusion-Weighted MR Imaging
por: Boraschi, Piero, et al.
Publicado: (2023)

Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience
por: Salati, Massimiliano, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_um27ajl34gookeh4tghmotc4am